Trials / Completed
CompletedNCT02115165
A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors
A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- Male
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
Cabazitaxel is a new generation taxane with a high capacity for blood-brain barrier crossing and limited peripheral neuro-toxicity, two major potential advantages in patients with advanced NSGCTs. Cabazitaxel has a broader in vitro spectrum of activity than docetaxel. Taxanes have demonstrated activity in pre-treated GCTs and are now part of standard treatment, but cabazitaxel has not yet been tested in patients with NSGCT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabazitaxel | On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², administered by IV route in 1 hour |
Timeline
- Start date
- 2014-07-23
- Primary completion
- 2022-04-29
- Completion
- 2023-04-24
- First posted
- 2014-04-15
- Last updated
- 2026-04-06
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02115165. Inclusion in this directory is not an endorsement.